AMGN — AMGEN INC
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 318154 ·
Last close
$457.93
Market Cap
$247.70B
52W High
$483.99
52W Low
$306.13
ADV30
2,645,699
Next earnings
2027-02-02
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 10,365,000,000 | 7,577,000,000 | 3,710,000,000 | 3,864,000,000 | 96,048,000,000 | 13,190,000,000 | 81,696,000,000 |
| Jun 2026 | 10,054,000,000 | 7,243,000,000 | 3,514,000,000 | 2,375,000,000 | 95,639,000,000 | 13,989,000,000 | 83,951,000,000 |
| Mar 2026 | 8,618,000,000 | 5,874,000,000 | 2,666,000,000 | 1,819,000,000 | 92,504,000,000 | 12,038,000,000 | 83,314,000,000 |
| Dec 2025 | 9,866,000,000 | 6,890,000,000 | 2,720,000,000 | 1,333,000,000 | 90,586,000,000 | 9,129,000,000 | 81,928,000,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$12,035,000,000
Investing CF
$-2,627,000,000
Financing CF
$-5,663,000,000
CapEx
$-2,454,000,000
Dividends Paid
$-5,366,000,000
Buybacks
—
EPS Diluted TTM
$17.24
As of
2026-11-08
Balance + Analyst (yfinance extras)
Retained Earnings
$-19,807,000,000
Inventory
$6,389,000,000
Receivables
$10,353,000,000
ST Investments
—
EBIT TTM
$13,688,000,000
Pretax Income TTM
$11,052,000,000
Interest Exp TTM
$2,636,000,000
Analysts
29
Yahoo Snapshot (yfinance, live)
Total Revenue
$38,903,001,088
EBITDA
$17,632,000,000
Free Cash Flow
$7,376,750,080
Enterprise Value
$289,863,467,008
Total Cash
$13,189,999,616
Total Debt
$54,007,001,088
Shares Out
540,911,490
Trailing EPS
$17.25
Book Value
$26.53
ROE
78.4%
ROA
8.9%
Div Yield
2.19%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 36,751,000,000 | 9,080,000,000 | 7,711,000,000 | 90,586,000,000 | 81,928,000,000 | 8,658,000,000 | 9,958,000,000 |
| Dec 2024 | 33,424,000,000 | 7,258,000,000 | 4,090,000,000 | 91,839,000,000 | 85,962,000,000 | 5,877,000,000 | 11,490,000,000 |
| Dec 2023 | 28,190,000,000 | 7,897,000,000 | 6,717,000,000 | 97,154,000,000 | 90,922,000,000 | 6,232,000,000 | 8,471,000,000 |
| Dec 2022 | 26,323,000,000 | 9,566,000,000 | 6,552,000,000 | 65,121,000,000 | 61,460,000,000 | 3,661,000,000 | 9,721,000,000 |
TTM Snapshot
Revenues TTM
$38,095,000,000
NetIncome TTM
$8,743,000,000
OpCashFlow TTM
—
Assets (Latest)
$95,639,000,000
Forward EPS
$24.99
Max Pain — expiry 2026-12-18
max pain strike: $420.00 · spot: $443.89 · call oi: 12,013 · put oi: 11,474
Expected Move to 2026-12-18:
±$30.10
(6.78%) —
implied range
$413.79 –
$473.99
· ATM straddle on $445.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| GILD | GILEAD SCIENCES, INC. | $211.18B | $170.26 | — |
| MRNA | Moderna, Inc. | $82.56B | $206.80 | — |
| ARGX | ARGENX SE | $58.92B | $947.52 | — |
| BIIB | BIOGEN INC. | $37.07B | $250.79 | — |
| RVMD | Revolution Medicines, Inc. | $35.19B | $162.69 | — |
News headlines (Yahoo Finance, 1h cache)
iShares Biotechnology ETF (IBB) Buys $16.2 Million More Gilead on Nov. 16
2026-11-18 11:05 · Yahoo
Biotechnology Market Companies 2027 Analysis: Amgen, Gilead, Regeneron, Vertex and Moderna Post Strong 2026 Results as Billion-Dollar Deals Reshape a Market Headed for USD 6.34 Trillion by 2035
2026-11-17 15:00 · Yahoo
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Nov. 13
2026-11-17 11:05 · Yahoo
Amgen (AMGN) Just Gave Investors Something To Think About
2026-11-16 21:12 · Yahoo
Dow Jones Biotech Giant Amgen In Buy Zone Amid Ongoing Stock Market Weakness
2026-11-16 17:59 · Yahoo
Novo Nordisk vs. Amgen: 1 Has the Blockbuster Weight-Loss Drugs, the Other Has a Promising Rival
2026-11-16 16:06 · Yahoo
Is Amgen Stock Still Telling Investors The Same Thing?
2026-11-16 08:08 · Yahoo
4 Dividend Stocks Retirees Can Buy Before They Go Ex-Dividend in the Week Ahead
2026-11-15 17:00 · Yahoo
Spdr Dow Jones (DIA) Sells Goldman Sachs and Caterpillar on Nov. 16
2026-11-18 11:04 · Yahoo
Anti-Obesity Drugs Market Companies Analysis 2027: Eli Lilly and Novo Nordisk Lead as Pfizer, Roche and Amgen Invest Billions to Challenge Them in a Market Headed for USD 64.96 Billion by 2035
2026-11-16 15:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.